The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
about
Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosisTuberculosis vaccines: beyond bacille Calmette-GuerinMethods and clinical development of adenovirus-vectored vaccines against mucosal pathogensRecent advances in the development of vaccines for tuberculosisVaccine development for tuberculosis: current progressFunctional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosisVaccines against tuberculosis: where are we and where do we need to go?Prime-boost approaches to tuberculosis vaccine developmentAdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human PrimatesA nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungsEffect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsA comparative analysis of polyfunctional T cells and secreted cytokines induced by Bacille Calmette-Guérin immunisation in children and adultsNovel vaccination strategies against tuberculosis.A review of the literature on the economics of vaccination against TB.Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination.The duration of antigen-stimulation significantly alters the diversity of multifunctional CD4 T cells measured by intracellular cytokine stainingExpanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatmentIncomplete recovery of pneumococcal CD4 T cell immunity after initiation of antiretroviral therapy in HIV-infected malawian adults.DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B elicits polyfunctional CD8(+) T cell responses.Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.Identification of Mycobacterium tuberculosis-specific Th1, Th17 and Th22 cells using the expression of CD40L in tuberculous pleurisy.Systemic BCG immunization induces persistent lung mucosal multifunctional CD4 T(EM) cells which expand following virulent mycobacterial challengeHigh-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protectionAerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.Identification of M. tuberculosis-specific Th1 cells expressing CD69 generated in vivo in pleural fluid cells from patients with tuberculous pleurisyDevelopment of an antibody to bovine IL-2 reveals multifunctional CD4 T(EM) cells in cattle naturally infected with bovine tuberculosisModification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responsesEvaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subsetSafety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection.Development of new vaccines and drugs for TB: limitations and potential strategic errorsIdentification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals.Vaccine against tuberculosis: what's new?Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.The frequencies of IFNγ+IL2+TNFα+ PPD-specific CD4+CD45RO+ T-cells correlate with the magnitude of the QuantiFERON® gold in-tube response in a prospective study of healthy indian adolescentsProtection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.
P2860
Q21135592-ED226A87-583C-4744-8D4F-7FEBD600B903Q22242669-75E304D4-A9FA-4A6E-BAB7-FD6835C03FE0Q26750912-10F7B581-4703-468B-AF0B-6F8A07C7F626Q26796440-37FE5F3F-50B2-4D3A-A79A-2D8913F34A96Q26827737-F432D473-3C31-4BAF-A989-A3960A77DB57Q26849399-3D3C50DA-768B-47B0-8F7D-72CD82279097Q26992233-87D1479F-D040-4ABE-B27F-9C6DFBDD97E3Q27024526-9A020895-5DAE-4B2B-9B17-79435710E152Q27300923-CF43A750-E096-4FD6-BDB4-E9EC1CDA3C11Q28396228-C26A1490-0B69-42D1-AB67-384A9330A03EQ28728311-6C1CC914-4D3A-457A-A400-730F0C7E717BQ28729028-15D7DF24-C930-497B-8213-524DA7D0470CQ30363188-1785E1E2-BA32-4EA8-8AD1-409916301014Q30413692-B9BF4AD9-8E44-4E5C-9B04-DA3FB644542FQ31028998-AF0A0A47-10B5-47A8-83F3-B771263F3C4BQ31068532-C92A5000-303F-48D6-A778-3C01E8495B77Q33614724-DC7CBC4B-53EF-4034-93A7-3EEDA2633222Q33800556-98CB02AF-388A-4849-983B-EB82745A92AFQ33850516-3B909BE2-699E-4959-B3C6-CDAFD143DF14Q33909362-10273A82-F941-45B9-9B40-FB4A535A8B7BQ33916768-826F646E-EA08-49C6-B4BE-49F1D5BD5C42Q33948002-04DEFCB6-CAE2-4B7F-8D93-DBFFF6901E2EQ33956033-0AA3BD0D-5586-4CA8-832B-1EAA5C9B57ACQ33992101-2F87FBBE-1D4B-4F9B-8596-65EE330C84CEQ34009517-4279FD18-F0D0-4670-8371-0A95986D5D70Q34117317-7C3976FC-D91C-4DE7-81C2-FEE66A093F3EQ34229968-35A29103-E0A7-4AB5-88F0-487738405FD7Q34289930-7D71A8E3-5297-4BAF-9B57-A78926C2FDB7Q34298351-C19B0920-E05D-4871-BCBA-F037B75E1D33Q34369139-9B85ED72-F219-4DBE-B8FF-F703AF71C78FQ34531535-C6B52BB7-6ACA-4BDD-B799-66F54591B6E9Q34566079-8DBDEC16-3D36-4422-B0A5-B3C05824A32DQ34663035-58F4B3C7-E8D5-47C6-B6D0-BF3CFA26D18AQ34804956-1CCF5AB9-DE36-4210-84A1-565E6FEF317CQ35065531-7A3A1612-5809-49D9-BF31-C34733CC5373Q35066262-E1A79638-3268-4AAF-B6D1-C2602F87AFDEQ35101472-739951B8-9D8D-4A42-8200-523858B2EF04Q35117812-72CBDB6F-7222-449C-9ED5-71930878D449Q35200725-561C41A8-8113-44B1-9350-D0A0A32EB638Q35301384-93F05473-029E-4183-9537-19C3A9F94E0F
P2860
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The novel tuberculosis vaccine ...... 4+ and CD8+ T cells in adults.
@ast
The novel tuberculosis vaccine ...... 4+ and CD8+ T cells in adults.
@en
type
label
The novel tuberculosis vaccine ...... 4+ and CD8+ T cells in adults.
@ast
The novel tuberculosis vaccine ...... 4+ and CD8+ T cells in adults.
@en
prefLabel
The novel tuberculosis vaccine ...... 4+ and CD8+ T cells in adults.
@ast
The novel tuberculosis vaccine ...... 4+ and CD8+ T cells in adults.
@en
P2093
P2860
P50
P1476
The novel tuberculosis vaccine ...... 4+ and CD8+ T cells in adults.
@en
P2093
Anthony Hawkridge
Ashley Veldsman
Brian Abel
Deborah Abrahams
Donata Sizemore
Gerrit Jan Weverling
Giulia Schirru
Hassan Mahomed
J Bruce McClain
Jacqueline Gearhart
P2860
P304
P356
10.1164/RCCM.200910-1484OC
P407
P577
2010-02-18T00:00:00Z